1. Home
  2. SOPH vs CTNM Comparison

SOPH vs CTNM Comparison

Compare SOPH & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SOPHiA GENETICS SA

SOPH

SOPHiA GENETICS SA

HOLD

Current Price

$8.79

Market Cap

462.3M

Sector

Health Care

ML Signal

HOLD

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$17.09

Market Cap

550.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOPH
CTNM
Founded
2011
2009
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
462.3M
550.7M
IPO Year
2021
2024

Fundamental Metrics

Financial Performance
Metric
SOPH
CTNM
Price
$8.79
$17.09
Analyst Decision
Strong Buy
Buy
Analyst Count
2
4
Target Price
$7.50
$19.00
AVG Volume (30 Days)
474.9K
492.0K
Earning Date
05-05-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.46
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$23.09
N/A
Revenue Next Year
$19.57
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.10
$8.60
52 Week High
$8.84
$17.35

Technical Indicators

Market Signals
Indicator
SOPH
CTNM
Relative Strength Index (RSI) 71.28 62.64
Support Level $4.63 $13.65
Resistance Level N/A N/A
Average True Range (ATR) 0.44 0.98
MACD 0.09 0.19
Stochastic Oscillator 84.06 85.85

Price Performance

Historical Comparison
SOPH
CTNM

About SOPH SOPHiA GENETICS SA

Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: